Burning Rock Biotech Ltd (BNR) is now in the Overvalued zone, suggesting that its current forward PS ratio of 1.58 is considered Overvalued compared with the five-year average of -8.39. The fair price of Burning Rock Biotech Ltd (BNR) is between 6.71 to 17.81 according to relative valuation method. Compared to the current price of 24.70 USD , Burning Rock Biotech Ltd By Overvalued By 38.65%.

Relative Value

Fair Zone

6.71-17.81

Current Price：24.70

38.65%

Overvalued

P/E

EV/EBITDA

EV/EBIT

P/S

P/OCF

P/FCF

Trailing

Forward

Unlock 5-Year Valuation Change

Is Burning Rock Biotech Ltd (BNR) at a historical peak or a rare bargain? Access the full 5-year trend to find out.

Unlock Now

Burning Rock Biotech Ltd (BNR) has a current Price-to-Book (P/B) ratio of 2.70. Compared to its 3-year average P/B ratio of 1.00, the current P/B ratio is approximately 169.21% higher. Relative to its 5-year average P/B ratio of 2.25, the current P/B ratio is about 19.76% higher. Burning Rock Biotech Ltd (BNR) has a Forward Free Cash Flow (FCF) yield of approximately -2.55%. Compared to its 3-year average FCF yield of -34.35%, the current FCF yield is approximately -92.57% lower. Relative to its 5-year average FCF yield of -27.18%, the current FCF yield is about -90.60% lower.

Competitors Valuation Multiple

AI Analysis

The average P/S ratio for BNR competitors is 1.06, providing a benchmark for relative valuation. Burning Rock Biotech Ltd Corp (BNR.O) exhibits a P/S ratio of 1.58, which is 49.7% above the industry average. Given its robust revenue growth of 2.31%, this premium appears unsustainable.

P/E

P/S

EV/EBITDA

EV/EBIT

Earnings Growth

Market Cap

Performance Decomposition

AI Analysis

Market capitalization of BNR increased by 0.00% over the past 1 year(s). The primary factor behind the change was an decrease in Unknown from 0.00 to 0.00.

The secondary factor is the Unknown, contributed 0.00% to the performance.

Overall, the performance of BNR in the past 1 year(s) is driven by Unknown.

People Also Watch

Frequently Asked Questions

Is BNR currently overvalued or undervalued?

Burning Rock Biotech Ltd (BNR) is now in the Overvalued zone, suggesting that its current forward PS ratio of 1.58 is considered Overvalued compared with the five-year average of -8.39. The fair price of Burning Rock Biotech Ltd (BNR) is between 6.71 to 17.81 according to relative valuation method. Compared to the current price of 24.70 USD, Burning Rock Biotech Ltd is Overvalued By 38.65%.

What is Burning Rock Biotech Ltd (BNR) fair value?

BNR's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. The fair price of Burning Rock Biotech Ltd (BNR) is between 6.71 to 17.81 according to relative valuation method.

How does BNR's valuation metrics compare to the industry average?

The average P/S ratio for BNR's competitors is 1.06, providing a benchmark for relative valuation. Burning Rock Biotech Ltd Corp (BNR) exhibits a P/S ratio of 1.58, which is 49.70% above the industry average. Given its robust revenue growth of 2.31%, this premium appears unsustainable.

What is the current P/B ratio for Burning Rock Biotech Ltd (BNR) as of Mar 03 2026?

As of Mar 03 2026, Burning Rock Biotech Ltd (BNR) has a P/B ratio of 2.70. This indicates that the market values BNR at 2.70 times its book value.

What is the current FCF Yield for Burning Rock Biotech Ltd (BNR) as of Mar 03 2026?

As of Mar 03 2026, Burning Rock Biotech Ltd (BNR) has a FCF Yield of -2.55%. This means that for every dollar of Burning Rock Biotech Ltd's market capitalization, the company generates -2.55 cents in free cash flow.

What is the current Forward P/E ratio for Burning Rock Biotech Ltd (BNR) as of Mar 03 2026?

As of Mar 03 2026, Burning Rock Biotech Ltd (BNR) has a Forward P/E ratio of -5.14. This means the market is willing to pay $-5.14 for every dollar of Burning Rock Biotech Ltd's expected earnings over the next 12 months.

What is the current Forward P/S ratio for Burning Rock Biotech Ltd (BNR) as of Mar 03 2026?

As of Mar 03 2026, Burning Rock Biotech Ltd (BNR) has a Forward P/S ratio of 1.58. This means the market is valuing BNR at $1.58 for every dollar of expected revenue over the next 12 months.

BNR Valuation